Activus to receive NEDO grant for 'Development of Innovative Ophthalmic Solutions'

Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), announces that its wholly owned subsidiary Activus Pharma Co., Ltd. ("Activus") is to receive a grant for its "Development of Innovative Ophthalmic Solutions" from the New Energy and Industrial Technology Development Organization (NEDO), an Incorporated Administrative Agency under the Ministry of Economy, Trade and Industry (METI) as a part of their FY2011 Innovation Promotion Programme.

The grant is awarded to private sector companies that focus on development of advanced technologies with practical application, and is intended to enhance the global competitiveness of Japanese companies, as well as to promote development of new industries.

Using Activus Pure Nano-particle Technology (APNT) and surface-modified nanoparticle technology, Activus is focusing on development of high value-added products that would solve the problems existing formulations are facing. To explore the potential of APNT in treatment of ophthalmic diseases, Activus has signed a collaboration agreement with Professor Hifofumi Takeuchi (Pharmaceutical Engineering Laboratory) and Professor Hideaki Hara (Laboratory of Molecular Pharmacology) of Gifu Pharmaceutical University and is now working on the development of novel posterior eye segment medication. Posterior eye segment disease such as diabetic retinopathy and age-related maculopathy is the primary cause of blindness and other visual impairments in middle age. An effective and easy-to-use medication has still not been invented, and the development of an innovative treatment is anticipated.

Within this subsidized project, Activus will be working on the development of novel ophthalmic solutions that would differ from the existing treatments because they would be delivered to the posterior eye segment. In that way, Activus would contribute to the QOL improvement in patients with visual impairments.

Up to two thirds of the development costs incurred for this project between 23 August 2011 and 28 February 2013 will be subsidized by the grant from NEDO.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Ex-eye bank workers say pressure, lax oversight led to errors